Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06300970
Other study ID # 0900f3eb81e634a9
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 9, 2022
Est. completion date August 16, 2023

Study information

Verified date May 2024
Source Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the efficacy of both first-line antimalarial medications used for the treatment of uncomplicated Plasmodium falciparum malaria infections in two geographic regions in Liberia.


Description:

Title: Efficacy of artesunate+amodiaquine (ASAQ) and artemether+lumefantrine (AL) for the treatment of uncomplicated Plasmodium falciparum malaria in Liberia Objective: To assess the efficacy of both first-line ASAQ and AL for the treatment of uncomplicated P. falciparum malaria infections Study Sites: Sacleapea Comprehensive Health Center, Saclepea-Mah District in Nimba County; and Sinje Health Center, Garwula District, Sinje, in Grand Cape Mount County Study Period: August 2022 to August 2023 Study Design: Prospective study of two cohorts with simultaneous enrolment of each therapy Patient population: Patients aged 6 to 59 months with confirmed uncomplicated P. falciparum infection Sample Size: Total number of patients to be enrolled is 352 patients. This consists of 88 patients per arm per site. There are two arms in each of the two sites. Treatment(s) and follow-up: Patients enrolled in the ASAQ arm will receive the treatment once daily dose for three days. Patients enrolled in the AL arm will receive treatment twice daily dose for three days. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy. Primary endpoints: The proportion of patients with early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response as indicators of efficacy. Recrudescence will be distinguished from re-infection by polymerase chain reaction (PCR) analysis. Secondary endpoints: The frequency and nature of adverse events will be recorded. Exploratory endpoints: Any polymorphisms of molecular markers for antimalarial drug resistance and prevalence of HRP2 deletions.


Recruitment information / eligibility

Status Completed
Enrollment 352
Est. completion date August 16, 2023
Est. primary completion date August 16, 2023
Accepts healthy volunteers No
Gender All
Age group 6 Months to 59 Months
Eligibility Inclusion Criteria 1. Age between 6 to 59 months (5 years) 2. Weight = 5 kg 3. Monoinfection with P. falciparum with a parasite density of 2,000 to 200,000 asexual forms per microliter of blood 4. Axillary temperature =37.5°C or history of fever in the last 24 hours 5. Hemoglobin = 8.0g/dl 6. Easy access to the health facility and ability to return to the health facility over the course of the four weeks of follow-up 7. Informed consent of parent or guardian Exclusion Criteria on Day 0 1. Any danger signs or signs of severe malaria (see Appendix I) 2. Pneumonia or bronchopneumonia 3. Severe malnutrition (Z-score < 3) 4. History of taking antimalarials (or antibiotics with antimalarial activity such as cotrimoxazole, tetracycline or doxycycline) in the last 14 days 5. Mixed malaria infection 6. History of hypersensitivity or allergy to the medication

Study Design


Intervention

Drug:
Amodiaquine-artesunate (ASAQ)
Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
Artemether+Lumefantrine (AL)
Oral medication given for treatment of uncomplicated plasmodium falciparum infection.

Locations

Country Name City State
Liberia Saclepea-Mahn Comprehensive Health Center Saclepea-Mahn District, Nimba County Saclepea Nimba County
Liberia Sinje Health Center, Garwula District, Sinje, Grand Cape Mount County Sinje Grand Cape Mount County

Sponsors (2)

Lead Sponsor Collaborator
Centers for Disease Control and Prevention Ministry of Health, Liberia

Country where clinical trial is conducted

Liberia, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of samples with confirmed Histidine-rich protein 2/3 (HRP2/3) gene deletions Molecular data on hrp2/hrp3 deletions will be tabulated and frequencies will be calculated from samples collected during the study, approximately 4 weeks. Samples collected from participants during the study, approximately 4 weeks.
Other Number of samples with molecular markers of anti-malarial resistance Molecular data on drug resistance polymorphisms will be tabulated and frequencies will be calculated from samples collected during the study, approximately 4 weeks. Samples collected from participants during the study, approximately 4 weeks.
Primary Number of Participants with Early Treatment Failure (ETF) Danger signs or severe malaria on day 1, 2, or 3 in the presence of parasitemia
A parasitemia on day 2 higher than day 0
Axillary temperature = 37.5 °C on day 3 in the presence of parasitemia
Parasitemia on day 3 = 25% of day 0 parasitemia
Day 1 to day 3 following treatment.
Primary Number of Participants with Late Treatment Failure (LTF) Danger signs, signs of severe malaria, or axillary temperature > 37.5 °C in the presence of parasitemia on any day between day 4 and day 28 in patients who did not previously meet any of the criteria of early treatment failure
Presence of parasitemia (with a parasite with the same genotype as day 0) on any day between day 7 and day 28 regardless of temperature in patients who did not previously meet any of the criteria of early treatment failure
Day 4 to day 28 following treatment.
Primary Number of Participants with Adequate Clinical and Parasitological Response (APCR) • Absence of parasitemia on day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure, reinfection or late parasitological failure. Day 28 following treatment.
Secondary Number of Patients with Adverse Events An adverse event is defined as any unfavorable, unintended sign, symptom, syndrome or disease that develops or worsens with the use of a medicinal product, regardless of whether it is related to the medicinal product during participation in the study, approximately 4 weeks. During participation in the study, approximately 4 weeks.
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Completed NCT02605720 - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns Phase 3